Ned Sacktor1, Kevin Robertson. 1. aDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Neurology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract
PURPOSE OF REVIEW: To describe the changes in the presentation of HIV-associated neurocognitive disorders (HAND) comparing the current combination antiretroviral therapy (cART) treatment era to the pre-cART era. RECENT FINDINGS: The frequency of the most severe stage of HAND, HIV-associated dementia (HAD), has decreased, but the frequencies of milder stages of HAND, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder, have increased. In the pre-cART era, HAD was a progressive disorder leading to death within months. With cART, HIV+ individuals with HAND frequently remain stable over many years, though they may still show signs of the ongoing central nervous system (CNS) injury. On neuropsychological testing, there may be a shift from the prominent slowed motor and speed of processing deficits in the pre-cART era to a greater impact on learning, memory, and executive functioning deficits in the cART era. Importantly, ANI has recently been shown to lead to a two-fold to five-fold increased progression to symptomatic HAND. Thus, early recognition and treatment of those with ANI is important to protect the CNS over the long term. SUMMARY: HAND continues to be an important neurological manifestation in both HIV+ individuals naïve to cART and on cART.
PURPOSE OF REVIEW: To describe the changes in the presentation of HIV-associated neurocognitive disorders (HAND) comparing the current combination antiretroviral therapy (cART) treatment era to the pre-cART era. RECENT FINDINGS: The frequency of the most severe stage of HAND, HIV-associated dementia (HAD), has decreased, but the frequencies of milder stages of HAND, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder, have increased. In the pre-cART era, HAD was a progressive disorder leading to death within months. With cART, HIV+ individuals with HAND frequently remain stable over many years, though they may still show signs of the ongoing central nervous system (CNS) injury. On neuropsychological testing, there may be a shift from the prominent slowed motor and speed of processing deficits in the pre-cART era to a greater impact on learning, memory, and executive functioning deficits in the cART era. Importantly, ANI has recently been shown to lead to a two-fold to five-fold increased progression to symptomatic HAND. Thus, early recognition and treatment of those with ANI is important to protect the CNS over the long term. SUMMARY: HAND continues to be an important neurological manifestation in both HIV+ individuals naïve to cART and on cART.
Authors: A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: R Scott Braithwaite; Amy C Justice; Chung-Chou H Chang; Jennifer S Fusco; Stephen R Raffanti; John B Wong; Mark S Roberts Journal: Am J Med Date: 2005-08 Impact factor: 4.965
Authors: R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant Journal: Neurology Date: 2010-12-07 Impact factor: 9.910
Authors: M H Wong; K Robertson; N Nakasujja; R Skolasky; S Musisi; E Katabira; J C McArthur; A Ronald; N Sacktor Journal: Neurology Date: 2007-01-30 Impact factor: 9.910
Authors: J T Becker; L Kingsley; J Mullen; B Cohen; E Martin; E N Miller; A Ragin; N Sacktor; O A Selnes; B R Visscher Journal: Neurology Date: 2009-10-20 Impact factor: 9.910
Authors: Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Ellen C Caniglia; Lauren E Cain; Amy Justice; Janet Tate; Roger Logan; Caroline Sabin; Alan Winston; Ard van Sighem; Jose M Miro; Daniel Podzamczer; Ashley Olson; José Ramón Arribas; Santiago Moreno; Laurence Meyer; Jorge del Romero; François Dabis; Heiner C Bucher; Gilles Wandeler; Georgia Vourli; Athanasios Skoutelis; Emilie Lanoy; Jacques Gasnault; Dominique Costagliola; Miguel A Hernán Journal: Neurology Date: 2014-06-06 Impact factor: 9.910
Authors: Kevin R Robertson; Noeline Nakasujja; Matthew Wong; Seggane Musisi; Elly Katabira; Thomas D Parsons; Allan Ronald; Ned Sacktor Journal: BMC Neurol Date: 2007-04-05 Impact factor: 2.474
Authors: J A Joska; J Witten; K G Thomas; C Robertson; M Casson-Crook; H Roosa; J Creighton; J Lyons; J McArthur; N C Sacktor Journal: AIDS Behav Date: 2016-08
Authors: Elizabeth C Pasipanodya; Jessica L Montoya; Laura M Campbell; Mariam A Hussain; Rowan Saloner; Emily M Paolillo; Dilip V Jeste; Scott L Letendre; J Allen McCutchan; Robert K Heaton; David J Moore Journal: Arch Clin Neuropsychol Date: 2021-02-12 Impact factor: 2.813
Authors: Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2016-08-02 Impact factor: 4.147
Authors: Brigid K Jensen; Hubert Monnerie; Maggie V Mannell; Patrick J Gannon; Cagla Akay Espinoza; Michelle A Erickson; Annadora J Bruce-Keller; Benjamin B Gelman; Lisa A Briand; R Christopher Pierce; Kelly L Jordan-Sciutto; Judith B Grinspan Journal: J Neuropathol Exp Neurol Date: 2015-11 Impact factor: 3.685
Authors: Rosemary Fama; Edith V Sullivan; Stephanie A Sassoon; Adolf Pfefferbaum; Natalie M Zahr Journal: Alcohol Clin Exp Res Date: 2016-10-19 Impact factor: 3.455